Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Monday that it has entered an agreement to acquire IDRx Inc, a Boston-based clinical-stage biopharmaceutical company, for up to USD1.15bn.
The acquisition includes IDRX-42, a selective KIT tyrosine kinase inhibitor (TKI) targeting gastrointestinal stromal tumours (GIST). GSK will pay USD1bn upfront, with an additional USD150m tied to regulatory milestones.
IDRX-42 is designed to address all primary and secondary KIT mutations that drive GIST progression, offering potential improvements in efficacy and tolerability over existing therapies. Recent phase I/Ib trial data demonstrated a 53% objective response rate in patients treated after one prior therapy, with a manageable safety profile.
GSK's expanding gastrointestinal cancer portfolio, which includes assets like dostarlimab and GSK5764227, underscores its focus on targeted mechanisms to address unmet medical needs. The acquisition aligns with GSK's growth ambitions through 2031 and beyond.
GIST is the most common subtype of soft tissue sarcoma, affecting up to 120,000 patients globally each year. Mutations in the KIT gene drive 80% of cases, with most first-line patients developing resistance mutations that lead to relapse. IDRX-42 has FDA Fast Track and Orphan Drug designations, highlighting its potential to fill critical gaps in treatment options.
The transaction, subject to regulatory approvals under the Hart-Scott-Rodino Act, also includes milestone payments and royalties to Merck KGaA, Darmstadt, Germany, for IDRX-42. Legal and financial advisory roles were provided by Centerview Partners, Goodwin Procter, and Leerink Partners.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review